ReviewBreathe (Sheffield, England)2026
Molecules of lung cancer - fusion alterations in nonsmall cell lung cancer: biology and diagnostic considerations.
Review in Breathe (Sheffield, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fusion alterations have transformed outcomes for a subset of patients with nonsmall cell lung cancer (NSCLC), as part of the evolution of precision oncology. While the role of molecular pathology in the diagnosis and treatment of NSCLC has rapidly evolved, it remains the responsibility of the pulmonologist to coordinate the diagnostic evaluation of patients with lung cancer, including clinical assessment, obtaining a histological diagnosis and coordination of staging procedures. This review focuses on the biology, clinical significance and diagnostic considerations of fusion alterations in NSCLC. We summarise current knowledge regarding the role of actionable gene fusion translocations, including anaplastic lymphoma kinase (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.